iTeos Therapeutics Announces Plan to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value

Reuters

05-28

<a href="https://laohu8.com/S/ITOS">iTeos Therapeutics</a> Announces Plan to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value

iTeos Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced its intention to wind down operations as part of a strategic review to maximize shareholder value. The decision follows a detailed assessment of the company's development pipeline, business prospects, and financial standing. The Board of Directors plans to cease clinical and operational activities while focusing on utilizing the company's cash reserves to deliver near-term shareholder value. This includes exploring the sale of key assets such as EOS-984, EOS-215, and a preclinical obesity program targeting ENT1. The company is aiming to identify and execute the best path forward to benefit its shareholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iteos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9458717-en) on May 28, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2538854476"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538854476\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2538854476?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-28 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538854476","market":"nz","top_or_hot":-1,"title":"iTeos Therapeutics Announces Plan to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ITOS\">iTeos Therapeutics</a> Announces Plan to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        iTeos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage biopharmaceutical company, has announced its intention to wind down operations as part of a strategic review to maximize shareholder value. The decision follows a detailed assessment of the company's development pipeline, business prospects, and financial standing. The Board of Directors plans to cease clinical and operational activities while focusing on utilizing the company's cash reserves to deliver near-term shareholder value. This includes exploring the sale of key assets such as EOS-984, EOS-215, and a preclinical obesity program targeting ENT1. The company is aiming to identify and execute the best path forward to benefit its shareholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iteos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9458717-en) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iTeos Therapeutics Announces Plan to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niTeos Therapeutics Announces Plan to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-28 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ITOS\">iTeos Therapeutics</a> Announces Plan to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        iTeos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage biopharmaceutical company, has announced its intention to wind down operations as part of a strategic review to maximize shareholder value. The decision follows a detailed assessment of the company's development pipeline, business prospects, and financial standing. The Board of Directors plans to cease clinical and operational activities while focusing on utilizing the company's cash reserves to deliver near-term shareholder value. This includes exploring the sale of key assets such as EOS-984, EOS-215, and a preclinical obesity program targeting ENT1. The company is aiming to identify and execute the best path forward to benefit its shareholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iteos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9458717-en) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDLBg3Ry:1","article_id":"2538854476","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538854476","pubTimestamp":1748435414,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"iTeos Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced its intention to wind down operations as part of a strategic review to maximize shareholder value. The decision follows a detailed assessment of the company's development pipeline, business prospects, and financial standing. The Board of Directors plans to cease clinical and operational activities while focusing on utilizing the company's cash reserves to deliver near-term shareholder value. This includes exploring the sale of key assets such as EOS-984, EOS-215, and a preclinical obesity program targeting ENT1. The company is aiming to identify and execute the best path forward to benefit its shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"iTeos Therapeutics宣布计划缩减业务并探索资产出售以实现股东价值最大化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ITOS":0.9,"NDAQ":0.9},"content_text":"iTeos Therapeutics Announces Plan to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value\n    \n\n        iTeos Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced its intention to wind down operations as part of a strategic review to maximize shareholder value. The decision follows a detailed assessment of the company's development pipeline, business prospects, and financial standing. The Board of Directors plans to cease clinical and operational activities while focusing on utilizing the company's cash reserves to deliver near-term shareholder value. This includes exploring the sale of key assets such as EOS-984, EOS-215, and a preclinical obesity program targeting ENT1. The company is aiming to identify and execute the best path forward to benefit its shareholders.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iteos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9458717-en) on May 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"event,express","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}